Search
01/02/2026
Early portopulmonary hypertension predicts mortality in patients with cirrhosis: Insights from the PORTO-DETECT cohort
Téllez, L, Donate, J, Guerrero, A, Beraza, IA, San Martín, D, Alvarado, E, Echevarria, V, Puente, A, Zamora, J, Del Prado, S, Tenes, A, Balagué, G, Vidal, B, Geli, C, Rodriguez-Gandia, MA, Baiges, A, Brujats, A, Rodríguez, DLH, Sánchez, SFG, Fortea, JI, del Cerro, MJ, Villanueva, C, Garcia-Pagán, JC, Giráldez, A, Albillos, A. Early portopulmonary hypertension predicts mortality in patients with cirrhosis: Insights from the PORTO-DETECT cohort. JOURNAL OF HEPATOLOGY. 2026; 84(2)DOI:10.1016/j.jhep.2025.09.011. PMID:41076090. IF:33.000(Q1/1D).
15/12/2025
Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia
Arguello-Tomas, M, Lynton-Pons, E, Albiol, N, Lopez-Ferrer, A, Sierra, J, Moga, E, Moreno, C. Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia. CANCER. 2025; 131(24)DOI:10.1002/cncr.70216. PMID:41378669. IF:5.100(Q1/3D).
01/12/2025
Pre-emptive TIPS should be considered in high-risk patients with both acute variceal bleeding and severe alcohol-related hepatitis
Rudler, M, Gea, VH, Larrue, H, Bouzbib, C, Procopet, B, Baiges, A, Turon, F, Villanueva, C, Albillos, A, Tapias, EA, Gluud, LL, Praktiknjo, M, Genesca, J, Ventura-Cots, M, Villagrasa, A, Rodrigues, S, Mouri, S, Giráldez-Gallego, A, Ridaura, HM, Laleman, W, Bureau, C, Robic, MA, Hartl, L, Tellez, L, Zipprich, A, Canete, N, Sultanik, P, Deckmyn, O, Mandorfer, M, Senzolo, M, Schepis, F, Tripathi, D, Pagan, JCG, Thabut, D. Pre-emptive TIPS should be considered in high-risk patients with both acute variceal bleeding and severe alcohol-related hepatitis. Jhep Reports. 2025; 7(12)DOI:10.1016/j.jhepr.2025.101611. PMID:41362711. IF:7.500(Q1/2D).
01/12/2025
Baseline Plasma Protein Signatures and Differential Molecular Responses to Dupilumab in Atopic Dermatitis Patients
Serra, E, Cantó, E, Gely, C, Pont, M, Trincado, J, Crespo, M, Vidal, S, Puig, L. Baseline Plasma Protein Signatures and Differential Molecular Responses to Dupilumab in Atopic Dermatitis Patients. JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2025; 145(12)DOI:. PMID:. IF:5.700(Q1/1D).
01/09/2025
Personalized dosing in MS: extended interval dosing of ocrelizumab, a real-world observational study
Martín-Aguilar, L, Blanco-Sanromán, N, Appiani, FE, Caballero-Avila, M, Vidal, N, Martínez-Martínez, L, Querol, L, Vidal-Jordana, A. Personalized dosing in MS: extended interval dosing of ocrelizumab, a real-world observational study. Multiple Sclerosis Journal. 2025; 31(3)DOI:. PMID:. IF:5.000(Q1/2D).
01/04/2025
Interplay of leucocyte-platelet complexes and clinical response to eltrombopag in immune thrombocytopenia patients
Osuna-Gómez, R, Zamora, C, Novelli, S, Garcia-Pallarols, F, Rodriguez, Y, Domingo, A, Canet, M, Olivera, P, Mulet, M, Cantó, E, Valcarcel, D, Sanchez-Gonzalez, B, Vidal, S. Interplay of leucocyte-platelet complexes and clinical response to eltrombopag in immune thrombocytopenia patients. BRITISH JOURNAL OF HAEMATOLOGY. 2025; 206(4)DOI:10.1111/bjh.19779. PMID:39327831. IF:3.800(Q1/3D).
01/01/2025
Risk scores predicting disease progression in early-stage CLL: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy
Arguello-Tomas, M, Mozas, P, Albiol, N, López-Esteban, M, Sierra, J, Nomdedéu, J, Martinez-Laperche, C, Moga, E, Piñeyroa, JA, Delgado, J, Osorio, S, Moreno, C. Risk scores predicting disease progression in early-stage CLL: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy. CANCER. 2025; 131(1)DOI:10.1002/cncr.35552. PMID:39264834. IF:5.100(Q1/3D).
04/04/2023
A multistrain probiotic increases the serum glutamine/glutamate ratio in patients with cirrhosis: a metabolomic analysis.
Laghi L, Román E, Lan Q, Nieto JC, Canalda-Baltrons A, Poca M, Sánchez-Rodríguez MB, Clària J, Alvarado E, Cuyàs B, Sánchez E, Vidal S, Guarner C, Escorsell À, Manichanh C, Soriano G. A multistrain probiotic increases the serum glutamine/glutamate ratio in patients with cirrhosis: a metabolomic analysis.. Hepatology Communications. 2023; 7(4)DOI:10.1097/HC9.0000000000000072. PMID:37026745. IF:5.600(Q1/2D).